Novel therapy for metabolic diseases through intestinal environment by intestinal hormone

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09417
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Metabolomics
• Research Institution: Keio University
• Principal Investigator: IRIE JUNICHIRO 慶應義塾大学, 医学部(信濃町), 講師 (70306687)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 腸内細菌 / 腸管ホルモン

Outline of Final Research Achievements

Dysbiosis reportedly occurs in patients with obesity and type 2 diabetes. Dysbiosis is considered to induce systemic chronic inflammation and the alteration of intestinal hormone secretion. These changes cause obesity and type 2 diabetes. The mechanism of dysbiosis remains to be elucidated. We have found that modulation of intestinal bile acid metabolism in the subjects with metabolic disorders prevented dysbiosis, preserved intestinal barriers, and prevented obesity dependent on intestinal microbiota, indicating that intestinal microbiota could be therapeutic targets in patients with the diseases.
We investigated the effects of incretin on metabolic parameters, microbiota, and immune cells in various mouse models and incretin was found to alter the intestinal environment. The mechanism by which incretin altered the intestinal function would be dependent on a suppression of inflammation. The intestinal inflammation could be the important target of metabolic disorders.

Free Research Field

エネルギー糖代謝